Celebrex News and Research

RSS

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer. It has the brand name Celebrex and Celebra (in other countries) for arthritis and Onsenal for polyps. Celecoxib is available by prescription in capsule form.

Potential safety risks with Celebrex

The Australian Therapeutic Goods Administration (TGA) has consulted today with the Chairs of its peak advisory committees, the Australian Adverse Drug Reactions Committee (ADRAC) and the Australian Drug Evaluation Committee (ADEC), about the latest research into the safety of the arthritis drug, Celebrex.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Celebrex like gene suppresses the growth of colon cancer

Cancer researchers at the Case Western Reserve University (Case) School of Medicine, University Hospitals of Cleveland (UHC) and the Howard Hughes Medical Institute have found a "Celebrex-like" gene that suppresses the growth of colon cancer.

13 Dec 2004

Celecoxib may regulate a cell's use of estrogen - might help explain the drug's anticancer properties

Six months of treatment with celecoxib (Celebrex) in women at risk of developing breast cancer results in the reduction of estrogen receptor expression in breast cells, a research team at The University of Texas M. D. Anderson Cancer Center has found.

13 Dec 2004

Greater risk of heart attack associated with Vioxx than Celebrex

In the first epidemiological study designed and executed specifically to determine the heart-attack risk associated with COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex), researchers at the University of Pennsylvania School of Medicine found a greater risk of heart attack associated with Vioxx than Celebrex, although neither of the two drugs showed a statistically significant elevated risk of heart attack relative to people who did not use the drugs.

8 Dec 2004

Use of the drug etodolac instead of drugs like Celebrex or Bextra could save $40 million annually

People in search of pain relief who take the generic anti-inflammatory etodolac suffer 60 percent fewer gastrointestinal complications than those who take similar drugs, according to researchers at UT Southwestern Medical Center at Dallas and the Dallas Veterans Affairs Medical Center.

14 Nov 2004

Celebrex may one day be used to prevent and even treat breast tumors

The anti-inflammatory drug Celebrex, or celecoxib, reduces tumor mass by encouraging cell death and discouraging both cell proliferation and the sprouting of new blood vessels that feed growing tumors, according to a study reported in the November issue of Molecular Cancer Research.

5 Nov 2004

Pfizer provides information about its COX-2 product Bextra (valdecoxib)

In view of the increased focus on alternative treatment options for people with arthritis, Pfizer is providing information to healthcare professionals about its COX-2 product Bextra® (valdecoxib).

18 Oct 2004

COX-2 agents have influenced the way physicians prescribe rheumatology medication

COX-2 agents, with their perceived reduction in side effects, have contributed substantially to a dramatic increase in NSAIDs (non-steroidal anti-inflammatory drugs) prescription utilization and influenced the way physicians prescribe rheumatology medication

18 Oct 2004

New survey reveals continued drug price disparities across the New York State

New York State Attorney General Eliot Spitzer has announced that his office's drug price website has been expanded to include pharmacies within every county in New York State.

11 Oct 2004

U.S. healthcare industry reaction to the withdrawal of Vioxx from the world-wide market

NDCHealth has announced U.S. healthcare industry reaction to the Sept. 30 announcement by Merck & Co. that it was withdrawing its anti-arthritic medication Vioxx from the world-wide market.

5 Oct 2004

First U.S. program to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada

Illinois Gov. Rod R. Blagojevich and Congressman Rahm Emanuel (D-Chicago) were joined in Chicago today by Wisconsin Governor Jim Doyle to launch the new I-SaveRx prescription drug importation program -- the first program in the nation to allow citizens to purchase lower cost, safe prescription drugs from Europe and Canada.

4 Oct 2004

Data demonstrate that Celebrex does not increase the risk of heart attack or stroke in patients with arthritis and pain

Pfizer has said that three large long-term Celebrex (celecoxib capsules) studies involving more than 6,000 patients have not shown any significant safety issues and are expected to continue to completion.

4 Oct 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

New medicare website shows inaccurate pricing

The new Medicare Web site with comparative prescription drug pricing contains inaccurate, erroneous information, sponsors of drug discount cards said on Friday. Companies offering the cards said the government and its contractor had posted inaccurate data just hours after the web site launch.

1 May 2004